Diplomat Pharmacy (NYSE:DPLO) Stock Price Up 8.8%

Share on StockTwits

Diplomat Pharmacy Inc (NYSE:DPLO) was up 8.8% on Tuesday . The company traded as high as $5.50 and last traded at $5.44, approximately 1,339,022 shares changed hands during trading. An increase of 26% from the average daily volume of 1,064,779 shares. The stock had previously closed at $5.00.

DPLO has been the topic of several recent analyst reports. Wells Fargo & Co boosted their target price on shares of Diplomat Pharmacy from $5.00 to $5.50 and gave the company a “market perform” rating in a report on Tuesday, August 13th. Deutsche Bank initiated coverage on Diplomat Pharmacy in a research report on Thursday, September 12th. They issued a “sell” rating and a $4.00 price objective for the company. ValuEngine raised Diplomat Pharmacy from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 29th. Zacks Investment Research downgraded Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research note on Friday, November 15th. Finally, Barclays lowered Diplomat Pharmacy from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $7.00 to $3.00 in a research report on Wednesday, November 13th. Four equities research analysts have rated the stock with a sell rating, ten have given a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $9.14.

The company has a debt-to-equity ratio of 0.18, a quick ratio of 0.36 and a current ratio of 0.55. The company has a 50 day moving average price of $4.96 and a 200 day moving average price of $5.23. The company has a market capitalization of $422.80 million, a price-to-earnings ratio of 27.48 and a beta of 0.92.

Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($2.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($2.15). Diplomat Pharmacy had a negative return on equity of 12.15% and a negative net margin of 12.47%. The firm had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.17 billion. The firm’s quarterly revenue was down 5.3% on a year-over-year basis. Research analysts forecast that Diplomat Pharmacy Inc will post -0.92 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its holdings in shares of Diplomat Pharmacy by 390.0% in the second quarter. JPMorgan Chase & Co. now owns 1,445,834 shares of the company’s stock valued at $8,632,000 after purchasing an additional 1,150,740 shares in the last quarter. Aperio Group LLC boosted its holdings in shares of Diplomat Pharmacy by 127.0% in the second quarter. Aperio Group LLC now owns 28,304 shares of the company’s stock worth $172,000 after acquiring an additional 15,834 shares during the period. A.R.T. Advisors LLC bought a new position in shares of Diplomat Pharmacy in the second quarter worth $433,000. Price T Rowe Associates Inc. MD grew its position in shares of Diplomat Pharmacy by 5.4% in the second quarter. Price T Rowe Associates Inc. MD now owns 192,456 shares of the company’s stock valued at $1,172,000 after purchasing an additional 9,800 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new position in shares of Diplomat Pharmacy in the second quarter valued at $192,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Diplomat Pharmacy Company Profile (NYSE:DPLO)

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Further Reading: Consumer behavior in bull markets

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.